Lead vaccine from Vical and Astellas flops in a Phase II herpes study
San Diego-based Vical $VICL says that its lead vaccine ASP0113 flopped in a Phase II study designed to thwart herpes in kidney transplant patients. The vaccine, partnered with Astellas in a $135 million deal that dates back to 2011, was supposed to knock down the proportion of patients having CMV infections, or viremia. But it failed the primary as well as secondary endpoints in the trial.
Vical’s shares dropped 18% in pre-market trading this morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.